CN115677813A - 化合物在tmem16a激动剂中的应用 - Google Patents
化合物在tmem16a激动剂中的应用 Download PDFInfo
- Publication number
- CN115677813A CN115677813A CN202210302603.1A CN202210302603A CN115677813A CN 115677813 A CN115677813 A CN 115677813A CN 202210302603 A CN202210302603 A CN 202210302603A CN 115677813 A CN115677813 A CN 115677813A
- Authority
- CN
- China
- Prior art keywords
- tmem16a
- compound
- alkyl
- independently selected
- caccs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 93
- 239000000556 agonist Substances 0.000 title claims abstract description 29
- 102000003787 Anoctamin-1 Human genes 0.000 title claims abstract description 6
- 108090000160 Anoctamin-1 Proteins 0.000 title claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 15
- 229940002612 prodrug Drugs 0.000 claims abstract description 12
- 239000000651 prodrug Substances 0.000 claims abstract description 12
- 206010008635 Cholestasis Diseases 0.000 claims abstract description 10
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 10
- 210000003079 salivary gland Anatomy 0.000 claims abstract description 10
- 206010013774 Dry eye Diseases 0.000 claims abstract description 9
- 208000005946 Xerostomia Diseases 0.000 claims abstract description 7
- 208000006673 asthma Diseases 0.000 claims abstract description 7
- 150000001408 amides Chemical class 0.000 claims abstract description 6
- 206010013781 dry mouth Diseases 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 claims abstract description 4
- 230000006589 gland dysfunction Effects 0.000 claims abstract description 4
- 235000000346 sugar Nutrition 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 27
- -1 chondroitin disaccharide Chemical class 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 150000002016 disaccharides Chemical class 0.000 claims description 14
- 150000002772 monosaccharides Chemical class 0.000 claims description 14
- 229920001282 polysaccharide Polymers 0.000 claims description 14
- 239000005017 polysaccharide Substances 0.000 claims description 14
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 12
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 150000004676 glycans Chemical class 0.000 claims description 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 10
- 125000003368 amide group Chemical group 0.000 claims description 10
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 10
- 125000005026 carboxyaryl group Chemical group 0.000 claims description 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
- 229910052805 deuterium Inorganic materials 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 9
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 8
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 8
- 241000720974 Protium Species 0.000 claims description 8
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 8
- 229910052722 tritium Inorganic materials 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 229920002567 Chondroitin Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 4
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims description 4
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 4
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 claims description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- 229940097043 glucuronic acid Drugs 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229940099552 hyaluronan Drugs 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 125000003071 maltose group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 208000032376 Lung infection Diseases 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000014304 histidine Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 235000018977 lysine Nutrition 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 235000008729 phenylalanine Nutrition 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 235000008521 threonine Nutrition 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 235000002374 tyrosine Nutrition 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 206010035664 Pneumonia Diseases 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000002685 pulmonary effect Effects 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 239000011575 calcium Substances 0.000 description 62
- 230000000694 effects Effects 0.000 description 52
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 32
- 102000011045 Chloride Channels Human genes 0.000 description 31
- 108010062745 Chloride Channels Proteins 0.000 description 31
- 230000028327 secretion Effects 0.000 description 26
- 108091006146 Channels Proteins 0.000 description 24
- MPDGHEJMBKOTSU-UHFFFAOYSA-N 10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 19
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 19
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 18
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 18
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 18
- 229960004949 glycyrrhizic acid Drugs 0.000 description 18
- 239000001685 glycyrrhizic acid Substances 0.000 description 18
- 235000019410 glycyrrhizin Nutrition 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 17
- 239000002994 raw material Substances 0.000 description 17
- 230000004913 activation Effects 0.000 description 15
- 229960003720 enoxolone Drugs 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 210000002919 epithelial cell Anatomy 0.000 description 12
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 11
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 11
- 229960000530 carbenoxolone Drugs 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 239000012190 activator Substances 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000003914 insulin secretion Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- YLFMCMWKHSDUCT-UHFFFAOYSA-N NS 1619 Chemical compound OC1=CC=C(C(F)(F)F)C=C1N1C(=O)NC2=CC(C(F)(F)F)=CC=C21 YLFMCMWKHSDUCT-UHFFFAOYSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000762 glandular Effects 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- ZUXNHFFVQWADJL-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(2-methoxyethyl)-n-(4-phenyl-1,3-thiazol-2-yl)benzamide Chemical compound N=1C(C=2C=CC=CC=2)=CSC=1N(CCOC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZUXNHFFVQWADJL-UHFFFAOYSA-N 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 210000000941 bile Anatomy 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 239000003596 drug target Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 102000000033 Purinergic Receptors Human genes 0.000 description 4
- 108010080192 Purinergic Receptors Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004561 lacrimal apparatus Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- JIVRLHBAUUZTNC-UHFFFAOYSA-N 2-[(4-methoxynaphthalen-2-yl)amino]-5-nitrobenzoic acid Chemical compound C=1C2=CC=CC=C2C(OC)=CC=1NC1=CC=C([N+]([O-])=O)C=C1C(O)=O JIVRLHBAUUZTNC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000037427 ion transport Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000012402 patch clamp technique Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- NWJZWHGSBTVTGM-UHFFFAOYSA-N 1-[bis(aziridin-1-yl)phosphoryl]-3-phenylurea Chemical compound C1CN1P(=O)(N1CC1)NC(=O)NC1=CC=CC=C1 NWJZWHGSBTVTGM-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102100022992 Anoctamin-1 Human genes 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 2
- 101000757261 Homo sapiens Anoctamin-1 Proteins 0.000 description 2
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003566 TRPV1 Human genes 0.000 description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
- 101150016206 Trpv1 gene Proteins 0.000 description 2
- SVJGGWZOTSJMCQ-RMTIMQEASA-N [(1s,2s,3r,4r,5s,6r)-2,3,4,5-tetrakis[bis(propanoyloxymethoxy)phosphoryloxy]-6-octoxycyclohexyl] butanoate Chemical compound CCCCCCCCO[C@@H]1[C@H](OC(=O)CCC)[C@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@H]1OP(=O)(OCOC(=O)CC)OCOC(=O)CC SVJGGWZOTSJMCQ-RMTIMQEASA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000009992 cAMP activation Effects 0.000 description 2
- 150000001669 calcium Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- 229940074774 glycyrrhizinate Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004495 interstitial cells of cajal Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- MXYATHGRPJZBNA-KRFUXDQASA-N isopimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@@](C=C)(C)CC2=CC1 MXYATHGRPJZBNA-KRFUXDQASA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004457 myocytus nodalis Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001913 submandibular gland Anatomy 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- MHVJRKBZMUDEEV-UHFFFAOYSA-N (-)-ent-pimara-8(14),15-dien-19-oic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)C=C1CC2 MHVJRKBZMUDEEV-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- MXYATHGRPJZBNA-UHFFFAOYSA-N 4-epi-isopimaric acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)CC1=CC2 MXYATHGRPJZBNA-UHFFFAOYSA-N 0.000 description 1
- GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 102100022991 Anoctamin-2 Human genes 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical group OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000012304 Bestrophin Human genes 0.000 description 1
- 108050002823 Bestrophin Proteins 0.000 description 1
- 108050003623 Bestrophin-1 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000757263 Homo sapiens Anoctamin-2 Proteins 0.000 description 1
- 101150006655 INS gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000011948 Multi-organ disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001744 Purinergic P2Y2 Receptors Human genes 0.000 description 1
- 108010029812 Purinergic P2Y2 Receptors Proteins 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 108091006518 SLC26A9 Proteins 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100035267 Solute carrier family 26 member 9 Human genes 0.000 description 1
- 102000003563 TRPV Human genes 0.000 description 1
- 108060008564 TRPV Proteins 0.000 description 1
- 102000003567 TRPV4 Human genes 0.000 description 1
- 101150098315 TRPV4 gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- FPNPSEMJLALQSA-MIYUEGBISA-N [[(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)[C@@H](O)C1 FPNPSEMJLALQSA-MIYUEGBISA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000005058 airway cell Anatomy 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 210000000741 bile canaliculi Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000010234 biliary secretion Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229950003387 denufosol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229950003529 diquafosol Drugs 0.000 description 1
- SYJFEGQWDCRVNX-UHFFFAOYSA-N diquat Chemical compound C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 SYJFEGQWDCRVNX-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 210000002372 intrahepatic bile duct epithelial cell Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 description 1
- 229960004508 ivacaftor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000017813 membrane repolarization Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- RMIVRCBSQPCSCQ-BDANYOJNSA-N methyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C RMIVRCBSQPCSCQ-BDANYOJNSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 230000037046 slow wave activity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229950005823 tezacaftor Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种化合物,其作为TMEM16A激动剂,如通式I所示,其可变异构体或其互变异构体,其药学上可接受的盐、前药和酯,其中各个取代基如权利要求所限定。本发明还提供了制备通式I的化合物的方法:其包括在适合的条件下反应,形成酰胺键或酯键,所述药物组合物在制备通过激动TMEM16A治疗疾病的药物中应用;其中所述疾病为囊性纤维化、唾液腺功能障、干眼症、口腔干燥症、胆汁淤积性肝病、糖尿病、肠动力减退症、慢性阻塞性肺炎、哮喘、肺部感染。
Description
技术领域
本发明涉及以一种化合物,其能够作为TMEM16A的激动剂。本发明还提供了该类化合物用于腺体分泌障碍类疾病中的应用。
背景技术
钙激活的氯通道(Calcium-activated chloride channels,CaCCs)广泛分布在内皮细胞、上皮细胞、血细胞等非兴奋细胞,以及心肌细胞、神经细胞、血管平滑肌细胞等可兴奋细胞。跨膜蛋白16A(transmembrane protein 16A,TMEM16A)是CaCCs的分子学基础。
腺上皮细胞是指一些具有分泌功能的上皮细胞,其分泌活动受到Cl–通道的精细调控。顶膜Cl–通道的活性决定着分泌液和电解质的流向和速率。Cl–依赖性的分泌通常与细胞内 cAMP和Ca2+两个第二信使有关。目前认为,除了cAMP激活的CFTR介导Cl–分泌外,TMEM16A/CaCCs介导了Cl–分泌在气道上皮细胞、泪腺、唾液腺、胆道、胰腺等多种上皮细胞/腺体的液体分泌过程中亦发挥重要作用。Schroeder等人,“Expression cloning ofTMEM16A as a calcium-activated chloride channel subunit(TMEM16A作为钙激活氯通道亚基的表达克隆)”,Cell,134(6):1019-1029(2008);还参见Yang等人,“TMEM16Aconfers receptor-activated calcium-dependent chloride conductance(TMEM16A给予受体激活的钙依赖的氯电导)”,Nature,455(7217):1210-1215(2008);以及Caputo等人,“TMEM16A,a membrane protein associated with calcium-dependent chloridechannel activity(TMEM16A,一种与钙离子依赖性氯离子通道活性有关的膜蛋白)”,Science,322(5901):590-594(2008)。
因此,TMEM16A/CaCCs被认为是囊性纤维化、唾液腺功能障、干眼症、口腔干燥症、胆汁淤积性肝病、糖尿病、胃肠动力减退症、慢性阻塞性肺炎、哮喘、肺部感染及其他与氯通道功能障碍相关疾病,特别是上皮细胞和腺体分泌障碍相关疾病的潜力药物作用靶点。
在治疗囊性纤维化上,囊性纤维化(cystic fibrosis,CF)是一种进行性,严重威胁生命的罕见遗传性多器官疾病。CF在全球范围内影响75000名患者,它是由CFTR(cysticfibrosis transmembrane conductance regulator)Cl–通道的功能缺失或突变引起Cl–分泌障碍,导致CF患者肺部、消化道、生殖道和身体其他部位水化不足而形成粘稠的粘液,进而引发严重的呼吸和消化问题以及其他并发症,例如反复支气管感染、气道阻塞和糖尿病。Reis 等人,“Cystic fibrosis(囊性纤维化)”,J Pediatr(Rio J),74Suppl 1 76-94(1998)。目前,福泰公司的三联疗法Trikafta(elexacaftor,ivacaftor,tezacaftor)是治疗CF的唯一药物(孤儿药)。三个药物成分分别通过恢复CFTR(F508del)突变体功能、延长其开放时间和促进其向细胞膜转运而纠正其缺陷。但已经鉴定出1900多个可能导致疾病表型的 CFTR突变,而Trikafta仅能用于携带F508del突变患者,且价格昂贵(311,000美元/年)。Boyle等人,“A new era in the treatment of cystic fibrosis:correction of theunderlying CFTR defect(囊性纤维化治疗的新纪元:纠正潜在的CFTR缺陷)”,LancetRespir Med,1(2): 158-163(2013)那些携带非F508del位点的CFTR突变患者迫切需要与突变无关的替代疗法。除了cAMP激活的CFTR介导Cl–分泌外,TMEM16A编码的Ca2+激活Cl–通道(TMEM16A/CaCCs)介导的Cl–分泌在上皮细胞/腺体分泌过程中亦发挥重要作用。Ousingsawat等人,“Loss of TMEM16A causes a defect in epithelial Ca2+-dependentchloride transport(TMEM16A的缺失导致上皮钙依赖性氯化物转运障碍)”,J Biol Chem,284: 28698-28703(2009)。呼吸道上皮细胞,嘌呤受体激活可引起细胞内cAMP和Ca2+浓度增加,继而激活cAMP-CFTR与Ca2+-TMEM16A/CaCCs两条通路,共同介导上皮细胞Cl–分泌,进而调节呼吸道表层的液体分泌量和组成。事实上,人气道上皮细胞 TMEM16A/CaCCs的mRNA水平远高于CFTR,TMEM16A敲除小鼠气道的嘌呤受体调节的CaCCs活性降低60%以上引起的水化不足导致气道内严重粘液积聚。Fischer等人,“CFTR and calcium-activated chloridechannels in primary cultures of human airway gland cells of serous or mucousphenotype(浆液或粘液表型人气道腺细胞原代培养物中的CFTR 和钙激活的氯离子通道)”,Am J Physiol Lung Cell Mol Physiol,299(4):585-594(2010);也参见Rock等人,“Transmembrane protein 16A(TMEM16A)is a Ca2+-regulated Cl-secretory channel inmouse airways[跨膜蛋白16A(TMEM16A)是小鼠气道中Ca2+调控的Cl-分泌通道]”,J BiolChem,284(22):14875-14880(2009)。这提示TMEM16A/CaCCs在呼吸道上皮Cl–的分泌活动中起重要作用,可以补偿CFTR功能缺失或突变引起Cl–分泌障碍,而不受CFTR突变类型的限制。因此,TMEM16A/CaCCs已经成为CF最具潜力的治疗靶点。 Sondo等人,“The TMEM16Achloride channel as an alternative therapeutic target in cystic fibrosis(TMEM16A氯通道作为囊性纤维化的替代治疗靶标)”,Int J Biochem Cell Biol, 52(73-76(2014)。
关于痰液稀释用于治疗慢性阻塞性肺病、严重哮喘以及肺部感染类疾病的应用上,同 CF病理表现相似,慢性阻塞性肺病、严重哮喘及由细菌、病毒引发的严重的肺部感染(如正在肆虐流行的2019新型冠状病毒肺炎),重症患者均表现出小气道黏液积聚,阻塞呼吸道,甚至出现急性呼吸窘迫综合征。清除痰液对于上述疾病的治疗意义重大。而除了通过抑制黏蛋白的产生和分泌,促进Cl–分泌带来的水化作用理论上可使痰液稀释,从而促进黏痰的排出。
在干眼症的治疗应用上,随着视频终端的普及和人口老龄化等原因,干眼症的发病率逐年升高。全球有超过10亿人存在不同程度的干眼症。TMEM16A/CaCCs在结膜、角膜以及泪腺中高表达,且泪腺中TMEM16A的mRNA水平显著高于结膜和角膜,这提示了 TMEM16A/CaCCs在泪腺分泌中可能发挥重要作用。Yu等人,“Regional differences in ratconjunctival ion transport activities(大鼠结膜离子转运活动的区域差异)”,Am JPhysiol Cell Physiol 303(7):C767-780(2012)。此外,TMEM16A/CaCCs也是地夸磷索(Dequafosol),一种干眼症的治疗药物的作用靶点之一。Nichols等人,B.Yerxa,“Diquafosol tetrasodium:a novel dry eye therapy(地夸磷索四钠:一种新的干眼症疗法)”,Expert Opin Investig Drugs, 13(1)47-54(2004)。因此,TMEM16A/CaCCs是治疗干眼症的重要的药物靶点。
在治疗口腔干燥症、干燥综合征上,口腔干燥症主要由唾液分泌减少或成分变化导致,常见于老年人和晚期癌症患者。65岁以上人群发生率可达30%~40%。TMEM16A/CaCCs 在颌下腺腺泡细胞的顶膜高表达,敲除TMEM16A/CaCCs使小鼠的颌下腺腺泡细胞分泌显著受损。使用siRNA敲低TMEM16A/CaCCs或使用其阻断剂可显著抑制唾液分泌。Romanenko等人,“Tmem16A encodes the Ca2+-activated Cl-channel in mousesubmandibular salivary gland acinar cells(Tmem16A编码小鼠下颌唾液腺腺泡细胞中的Ca2+激活的Cl-通道)”,J Biol Chem,285(17):12990-13001(2010);也参考Catalan等人,“A fluid secretion pathway unmasked by acinar-specific Tmem16A gene ablationin the adult mouse salivary gland (成年小鼠唾液腺中未被腺泡特异性Tmem16A基因消融掩盖的液体分泌途径),Proc Natl Acad Sci U S A,112(7):2263-2268(2015)。这提示TMEM16A/CaCCs在唾液分泌中发挥重要作用,有可能成为唾液腺功能障碍性疾病(如干燥综合症、放射性损伤引发的口腔干燥症)最具潜力的治疗靶点。
在治疗胆汁淤积性肝病上,胆汁淤积性肝病是由各种原因引起的胆汁生成、分泌和排泄障碍,不能主动经胆小管排至肠腔,在肝内淤积,反流入血,而引起的一系列器质性损害、代谢失调和功能紊乱的肝胆系统疾病。肝内胆管上皮细胞(intrahepatic bile ductepithelial cells,BECs),也称为胆管细胞,通过分泌电解质和水促进胆汁形成,而BECs顶膜或腔膜上的Cl-通道为胆汁的分泌和排泄提供动力。目前的研究表明,TMEM16A是人、大鼠和小鼠胆管上皮细胞中Ca2+激活氯通道的分子基础,也被确认为是影响胆汁分泌的重要的Cl-通道。Dutta等人,“Identification and functional characterization of TMEM16A,a Ca2+-activated Cl-channel activated by extracellular nucleotides,in biliaryepithelium(胆管上皮细胞TMEM16A(一种被细胞外核苷酸激活的Ca2+激活的Cl-通道)的鉴定和功能表征”,J Biol Chem,286(1):766-776(2011)。TMEM16A/CaCCs还介导胆汁酸引发的胆汁分泌增加。 Li等人,“Bile acids stimulate cholangiocyte fluid secretion byactivation of transmembrane member 16A Cl-channels(胆汁酸通过激活跨膜成员16ACl-通道刺激胆管细胞液分泌)”, Hepatology,68(1):187-199(2018)。这表明,TMEM16A/CaCCs是调节胆汁淤积性肝病治疗中胆汁形成的药物靶点。此外,TMEM16A/CaCCs还广泛分布于乳腺、汗腺、肠上皮、胰腺等部位,介导Cl–分泌。Kamikawa等人,“Ca2+-activated Cl-channel currents in mammary secretory cells from lactating mouse(泌乳小鼠乳腺分泌细胞中Ca2+激活的Cl-通道电流)”, Am J Physiol Cell Physiol,311(5):C808-C819(2016);Ertongur等人,“A novel TMEM16A splice variant lacking the dimerizationdomain contributes to calcium-activated chloride secretion in human sweatgland epithelial cells(缺乏二聚化结构域的新型TMEM16A剪接变体有助于人类汗腺上皮细胞中钙激活的氯化物分泌)”,Exp Dermatol,23(11):825-831 (2014)也参考Kunzelmann,“Control of Ion Transport by Tmem16a Expressed in Murine Intestine(小鼠肠中表达的Tmem16a对离子运输的控制)”,Front Physiol,10(1262(2019)。
在治疗II型糖尿病上,除上述外分泌腺外,TMEM16A/CaCCs也表达于重要的内分泌腺并且发挥重要作用。例如,它表达于胰岛β细胞中,并介导葡萄糖诱导的β细胞的Cl-流出。在该细胞中也观察到典型的TMEM16A/CaCCs电流。此外,阻断TMEM16A/CaCCs不但可以抑制胰岛素分泌,还导致葡萄糖刺激的动作电位速率大大降低,并引起部分膜复极化。这说明,TMEM16A/CaCCs对于维持葡萄糖刺激的膜电位振荡和胰岛素分泌至关重要。 Crutzen等人,“Anoctamin 1(Ano1)is required for glucose-induced membrane potentialoscillations and insulin secretion by murine beta-cells(鼠β细胞对葡萄糖诱导的膜电位振荡和胰岛素分泌需要Ano1)”,Pflugers Arch,468(4):573-591(2016)。在基因水平上,人胰岛中胰岛素(insulin,INS)启动子附近区域与TMEM16A/CaCCs基因之间存在物理接触,这种接触可以随着葡萄糖的刺激而加强葡萄糖并且上调TMEM16A/CaCCs表达,而对INS基因转录的抑制则降低了TMEM16A/CaCCs的表达。此外,TMEM16A/CaCCs的敲低会导致胰岛素分泌的显著降低。Xu等人,“Mapping of long-range INS promoter interactionsreveals a role for calcium-activated chloride channel ANO1 in insulinsecretion(远程INS启动子相互作用的映射揭示了钙激活的氯离子通道ANO1在胰岛素分泌中的作用)”,Proc Natl Acad Sci USA,111(47):16760-16765(2014)。这些研究表明,TMEM16A/CaCCs对于调控胰岛素的分泌发挥重要作用,也是治疗II型糖尿病的药物靶点。
在治疗胃肠动力减退类疾病上,胃肠动力减退是一种慢性疾病,严重影响患者的生活质量。这类疾病可发生在胃肠道的任何部位,包括一系列广泛的体征和症状,对个体患者和整个社会都造成了巨大的影响。PMID:16849850目前的研究表明,TMEM16A/CaCCs 在平滑肌收缩的过程中也至关重要。TMEM16A/CaCCs在气道平滑肌细胞、血管平滑肌细胞和生殖道的平滑肌细胞中表达,并且对于气道平滑肌的收缩,血压的控制以及生育活动发挥重要作用。Huang等人,“Studies on expression and function of the TMEM16A calcium-activated chloride channel(TMEM16A钙激活的氯离子通道的表达和功能研究)”, ProcNatl Acad Sci U S A,106(50):21413-21418(2009);Davis等人,“Expression profileand protein translation of TMEM16A in murine smooth muscle(TMEM16A在鼠平滑肌中的表达及蛋白翻译)”,Am J Physiol Cell Physiol,299(5):C948-959(2010)。有趣的是, TMEM16A/CaCCs不表达于胃肠道平滑肌细胞,但存在于控制平滑肌收缩的肠间质起搏器细胞(Interstitial cells of cajal,ICC)中。在胃肠道中,SMC的收缩受起搏器细胞ICC的控制。ICC产生的起搏器活动会在电耦合的SMC中感应出有节奏的慢波,从而控制肠收缩活动的频率和传播特性。Sanders,“Interstitial cells of cajal as pacemakers inthe gastrointestinal tract(肠间质细胞作为胃肠道中的起搏器)”,Annu Rev Physiol,68(307-343(2006)此外, TMEM16A/CaCCs阻断剂,尼氟酸等以浓度依赖的方式阻断了鼠类,灵长类动物,人小肠和胃中的慢波并降低其收缩频率。TMEM16A基因敲除小鼠的胃肠平滑肌节律性收缩减弱也强调了TMEM16A对于胃肠道平滑肌活动的生理重要性。Hwang等人,“Expression of anoctamin 1/TMEM16A by interstitial cells of Cajal isfundamental for slow wave activity in gastrointestinal muscles(肠间质细胞表达的anoctamin 1/TMEM16A是胃肠道肌肉中慢波活动的基础)”,J Physiol,587(Pt 20):4887-4904(2009);Singh等人,“Ano1,a Ca2+-activated Cl-channel,coordinatescontractility in mouse intestine by Ca2+transient coordination betweeninterstitial cells of Cajal(Ano1,Ca2+激活的Cl-通道,通过肠间质细胞之间的Ca2+瞬时协调来调节小鼠肠道的收缩性)”,J Physiol,592(18):4051-4068(2014)。相反,Eact等TMEM16A/CaCCs开放剂则显示出促进肠蠕动的药理学作用。Namkung等人, “Small-molecule activators of TMEM16A,a calcium-activated chloride channel,stimulateepithelial chloride secretion and intestinal contraction(钙激活的氯离子通道TMEM16A的小分子激活剂,刺激上皮氯化物的分泌和肠道收缩)”,FASEB J,25(11):4048-4062(2011)。因此,TMEM16A/CaCCs也是治疗肠动力减退类疾病的重要药物靶点。
目前,CaCCs激动剂有两个研发策略:(1)胞浆Ca2+激动剂,可通过升高胞浆Ca2+而间接激活CaCCs。然而这类激动剂通常只能引起胞浆Ca2+短暂的升高。最近报道嘌呤P2Y2 受体激动剂Denufosol的囊性纤维化Ⅲ期试验未能显示出临床疗效,这可能是因为它消耗细胞内Ca2+储存并降低了受体敏感性而导致药物的作用时间短暂。(2)TMEM16A/CaCCs直接激动剂,由于TMEM16A/CaCCs的激活受到Ca2+的直接调控,因此,TMEM16A/CaCCs 的增效剂也属于直接激活剂,该类药物通过增加该通道对Ca2+的敏感性使其在细胞内存在基础Ca2+情况下而被激活。理论上,直接作用于TMEM16A/CaCCs的激动剂与胞浆Ca2+激动剂相比具有三个方面的优势:①靶向特异性:除TMEM16A编码CaCCs外,TMEM16B、 Bestrophin-1、SLC26A9也可编码CaCCs,胞浆Ca2+激动剂对不同基因编码的CaCCs的激活作用没有特异性。而选择性TMEM16A/CaCCs激动剂具有很高的靶向特异性,这将降低药物可能产生的副作用;②作用持久:与胞浆Ca2+激动剂相比,TMEM16A/CaCCs激动剂可以产生持久的CaCCs激活作用,从而具有更大的疗效;③保护细胞:Ca2+激动剂升高细胞内钙的同时,不可避免地会引起细胞钙超载继而产生细胞凋亡等情况。TMEM16A/CaCCs 直接激动剂则避免此种情况发生。因此,开发TMEM16A/CaCCs直接激动剂已成为药物研发的优先方向。
然而,与TMEM16A/CaCCs阻断剂研发相比,其开放剂的研发情况不容乐观。目前,已知的TMEM16A/CaCCs的直接激动剂非常有限。(1)代号ETX001,目前结构尚未公开,是英国Enterprise Therapeutics生物医药公司开发的TMEM16A/CaCC激动剂 (potentiator),它可以恢复原代CF细胞的阴离子电导和液体分泌,并提高在体粘液纤毛清除率[1]。这为囊性纤维化、慢性阻塞性肺病和严重哮喘提供潜在的新疗法。Danahay等人,“TMEM16APotentiation:A Novel Therapeutic Approach for the Treatment of CysticFibrosis(TMEM16A增效:一种新型的治疗囊性纤维化的治疗方法),Am J Respir CritCare Med,201(8):946-954(2020)。(2)代号Eact(Cas:461000-66-8),最早被报道,也是受关注度最高的一个。Namkung等人,“Small-molecule activators of TMEM16A,a calcium-activated chloride channel,stimulate epithelial chloride secretion andintestinal contraction(TMEM16A的小分子激活剂,钙激活的氯离子通道,刺激上皮氯化物的分泌和肠收缩)”,FASEB J,25(11):4048-4062(2011)。然而,Eact被证明是通过升高细胞内 Ca2+而发挥的间接作用。Liu等人,“Eact,a small molecule activator of TMEM16A,activates TRPV1 and elicits pain-and itch-related behaviours(Eact是TMEM16A的小分子激活剂,可激活TRPV1并引发与疼痛和瘙痒相关的行为)”,Br J Pharmacol,173(7):1208-1218 (2016);也参见,Genovese等人,“TRPV4 and purinergic receptorsignalling pathways are separately linked in airway epithelia to CFTR andTMEM16A chloride channels(TRPV4和嘌呤能受体信号通路在气道上皮中分别与CFTR和TMEM16A氯化物通道相连)”,J Physiol, 597(24):5859-5878(2019)。同时被报道的Fact(potentiator,484039-66-9)属于 TMEM16A/CaCCs的增效剂但作用相对较弱。(3)INO-4995(Cas:868171-91-9),可激活外源性表达的TMEM16A/CaCCs,但对爪蟾卵母细胞、人气道和结肠细胞内源性 TMEM16A/CaCCs电流无作用。Tian等人,“Control of TMEM16A by INO-4995and other inositolphosphates(INO-4995和其他肌醇磷酸酯对TMEM16A的调节)”,BrJ Pharmacol, 168(1):253-265(2013)。(4)NS1619(Cas:153587-01-0),大电导钙激活钾通道(BKCa) 的激动剂,可激动小鼠门静脉及兔肺动脉平滑肌细胞内源性CaCCs。Saleh等人,“Stimulation of Ca2+-gated Cl-currents by the calcium-dependent K+channelmodulators NS1619[1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzi midazol-2-one]and isopimaric acid(钙赖性K+通道调节剂NS1619[1,3-二氢-1-[2-羟基-5- (三氟甲基)苯基]-5-(三氟甲基)-2H-苯并咪唑-对Ca2+门控Cl-电流的刺激2-一]和异海藻酸)”,J Pharmacol Exp Ther,321(3):1075-1084(2007)。(5)天然化合物人参皂苷[2,3]以及壳寡糖低聚物[4],可以增大外源性表达的TMEM16A/CaCCs电流,并增强豚鼠回肠收缩幅度和频率。Guo等人,“Ginsenoside Rb1,anovel activator of the TMEM16A chloride channel,augments the contraction ofguinea pig ileum(人参皂苷Rb1,TMEM16A氯化物通道的新型激活剂,增加了豚鼠回肠的收缩)”,Pflugers Arch,469(5-6):681-692(2017);还参考Guo等人,“The MolecularMechanism of Ginsenoside Analogs Activating TMEM16A (人参皂苷类似物激活TMEM16A的分子机制)”,Biophys J,118(1):262-272(2020);以及Guo等人,“Entering thespotlight:Chitosan oligosaccharides as novel activators of CaCCs/TMEM16A(备受关注:壳聚糖低聚糖作为CaCCs/TMEM16A的新型激活剂)”, Pharmacol Res,146(104323(2019)。鉴于开发TMEM16A/CaCC开放剂重要的临床意义和社会应用价值,其研发既具有紧迫性又充满竞争性。
通过上述项目开发可以看出,目前急需寻找一种对能够对TMEM16A/CaCCs作用强烈的激动剂,能够治疗相关疾病。
发明内容
本发明针对目前临床上腺体分泌障碍类疾病没有有效药物的问题,提出了通过本发明化合物针对TMEM16A激动剂的方案。
具体来说,本发明通过如下技术方案实现的。
本发明提供如下通式I的化合物,作为TMEM16A激动剂的应用,其可变异构体或其互变异构体,其药学上可接受的盐、前药和酯,
其中,R1独立地选自-S-R3或-O-R3;
R2独立地选自-NR5R6或-O-R7;
R3独立地选自氢、氕、氘、氚、-(C=O)R4,单糖糖基、二糖糖基、多糖糖基、R4取代的单糖糖基、R4取代的二糖糖基、R4取代的多糖糖基;
R4独立地选自烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代;
所述单糖糖基的糖是葡萄糖,甘露糖、半乳糖、果糖、阿拉伯糖,木糖,D-核糖、脱氧核糖、鼠李糖、半乳糖醛酸、葡萄糖醛酸、山梨糖醇;
所述二糖糖基的糖是麦芽糖、异麦芽糖、乳糖、纤维二糖、蔗糖、龙胆二糖、海藻二糖、蜜二糖、软骨素二糖、透明质二糖、菊粉二糖;
所述多糖是至少2个单糖连接而成;
R5、R6、R7独立地选自氢、氕、氘、氚、烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被 0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代;
-NR5R6是氨基酸的氨基端的一个H被取代后形成基团,所述氨基酸选自甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、甲硫氨酸、脯氨酸、色氨酸、丝氨酸、酪氨酸、半胱氨酸、苯丙氨酸、天冬酰胺、谷氨酰胺、苏氨酸、天冬氨酸、谷氨酸、赖氨酸、精氨酸或组氨酸。
其中所述R1是-O-R3;
R2是-O-R7;
R3独立地选自氢、氕、氘、氚、-(C=O)R4,单糖糖基、二糖糖基、多糖糖基、R4取代的单糖糖基、R4取代的二糖糖基、R4取代的多糖糖基;
R4独立地选自烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代;
所述单糖糖基的糖是葡萄糖,甘露糖、半乳糖、果糖、阿拉伯糖,木糖,D-核糖、脱氧核糖、鼠李糖、半乳糖醛酸、葡萄糖醛酸、山梨糖醇;
所述二糖糖基的糖是麦芽糖、异麦芽糖、乳糖、纤维二糖、蔗糖、龙胆二糖、海藻二糖、蜜二糖、软骨素二糖、透明质二糖、菊粉二糖;
所述多糖是至少2个单糖连接而成;
R7独立地选自氢、氕、氘、氚、烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代。
进一步,其中所述R1是-O-R3;R2是-O-R7,R3独立地选自H、氘、-(C=O)R4,单糖糖基、二糖糖基、多糖糖基;
R4独立地选自烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代;
进一步地,所述化合物选自如下化合物:
进一步地,所述化合物选自如下化合物:
本发明化提供一种制备通式I的化合物的方法:其包括使式II的化合物在适合的条件下反应,形成酰胺键或酯键,其中R1如权利要求1中所定义,
本发明还提供一种制备通式I的化合物的方法:其包括使式III的化合物在适合的条件下反应,形成酰胺键、酯键或-O-,其中R2如权利要求1中所定义
本发明还提供一种药物组合物,包含权利要求1-5所述化合物、其可变异构体或其互变异构体、其药学上可接受的盐、前药或酯,以及可药用赋形剂或载体。
本发明还提供上述化合物、其可变异构体或其互变异构体、其药学上可接受的盐、前药或酯和权利要求8所述药物组合物在制备通过激动TMEM16A治疗疾病的药物中应用。
本发明还提供上述化合物的应用,其中所述疾病为囊性纤维化、唾液腺功能障、干眼症、口腔干燥症、胆汁淤积性肝病、糖尿病、肠动力减退症、慢性阻塞性肺炎、哮喘、肺部感染。
本发明的有益技术效果如下:
本发明化合物可极大的增强TMEM16A/CaCCs电流,与已报道的TMEM16A/CaCCs 激动剂的作用相比,其效价更高、效能更大,且不影响细胞内钙水平。这表明,本发明化合物是通过直接作用于TMEM16A/CaCCs而发挥作用的。
本发明首次证实本发明化合物对TMEM16A的作用,并进一步用于相应的疾病治疗,这在开
本发明系列化合物对TMEM16A/CaCCs的作用更强,本发明化合物中部分化合物属于中药成,具有成药性更强的特点。
附图说明
图1:本发明系列化合物可以治疗相关疾病机理图。
图2:本发明化合物1-1,1-2,1-3对外源性表达的TMEM16A/CaCCs的增大作用。a:记录所用电压刺激程序。b:18β-GA和GL对TMEM16A/CaCCs的作用典型图;18α-GA 和CBX对TMEM16A/CaCCs的作用典型图。c:所测化合物(30μM)对+80mV下 TMEM16A/CaCCs电流作用的统计结果。
图3:本发明化合物1-1对外源性表达的TMEM16A/CaCCs的增大作用的药理学鉴定。a-b:TMEM16A/CaCCs阻断剂MONNA(10μM)、千金藤素(30μM)对18β-GA(30μM) 激活的TMEM16A/CaCCs的作用时程图及统计结果。c:记录所用电压刺激程序。d:统计结果。■:+80mV;●:–80mV。
图4:本发明化合物1-1,1-2,1-3对外源性表达的TMEM16A/CaCCs的增大作用的量效关系。
a:不同浓度18β-GA激活TMEM16A/CaCCs的时程图。电流幅度以给药前电流进行了标准化。不同浓度18β-GA作用的典型电流图,电流图取自对应时程图a-f中标注位置的,并以给药前电流幅度进行了标准化。b:18β-GA、18α-GA及CBX的量效关系曲线。
图5:本发明化合物1-1,1-2,1-3对外源性表达的TMEM16A/CaCCs通道动力学的调节作用。a:电流记录所用电压刺激程序。b:给药前后TMEM16A/CaCCs电流典型图.c:统计结果,以给药前+80mV电流幅度进行标准化。
图6:本发明化合物1-1与目前已知化合物增大TMEM16A/CaCCs的对比数据结果。a:记录所用电压刺激程序。b:18β-GA和Eact对TMEM16A/CaCCs的作用典型图。c:18β-GA 和NS1619对TMEM16A/CaCCs的作用典型图。d:所测化合物(30μM)对+80mV下 TMEM16A/CaCCs电流作用的统计结果。
图7:本发明化合物1-1增大TMEM16A/CaCCs的作用与其升高内钙的作用无关。a-c:18β-GA、GL及TG对细胞内钙作用时程图。d-e:18β-GA、GL及TG对TMEM16A/CaCCs 作用时程图。f:统计结果。
图8:本发明化合物1-1增大TMEM16A/CaCCs的内钙依赖性。a-b:采用BAPTA鳌和细胞内钙(0[Ca2+]i),18β-GA对TMEM16A/CaCCs的作用时程图、典型电流图及统计结果。c-d:不同浓度[Ca2+]i情况下,18β-GA对TMEM16A/CaCCs的作用的典型电流图及统计结果。
图9:本发明化合物1-1对分泌细胞外源性表达的TMEM16A/CaCCs的增大作用。a:18β-GA(30μM)对LA795、A549、MCF-7等腺细胞内源性表达的TMEM16A/CaCCs的增大作用典型电流图。b:18β-GA(30μM)对HCE、HBE和HCjE上皮细胞内源性表达的TMEM16A/CaCCs的增大作用典型电流图。c:18β-GA(30μM)对各类细胞+80mV下 TMEM16A/CaCCs电流作用的统计结果。
具体实施方式
以下结合技术方案和附图详细说明本发明的具体实施例。
本发明提供了如下通式化合物,其作为TMEM16A激动剂,如通式I所示,其可变异构体或其互变异构体,其药学上可接受的盐、前药和酯,
其中,R1独立地选自-S-R3或-O-R3;R2独立地选自-NR5R6或-O-R7;
对于TMEM16A的激动剂,通式的母核结构结构是必须,无论R1是什么基团,只要是可以分解成为羟基和巯基都是可以,R2无论是什么基团,只要是可以最终羧酸即可,所以是酰胺键或者酯键都可以。
上述所述的“分解”一般是指体内降解,包括胃酸的条件下降解,也包括在细胞微环境的降解。
在一种具体实施方式中,本发明化合物包括但不限于甘草酸,甘草次酸,18α-甘草次酸(18α-GA)、18β-甘草次酸(18β-GA)、甘草酸烷基酯,甘草次酸烷基酯,18α-甘草次酸烷基酯、18β-甘草次酸烷基酯、甘草酸芳香酯,甘草次酸芳基酯,18α-甘草次酸芳基酯、 18β-甘草次酸芳基酯、甘草酸脂肪酰胺,甘草次酸脂肪酰胺,18α-甘草次酸脂肪酰胺、18β- 甘草次酸脂肪酰胺、甘草酸芳酰胺,甘草次酸芳酰胺,18α-甘草次酸芳酰胺、18β-甘草次酸芳酰胺、与氨基酸以肽键形成的甘草酸衍生物、与氨基酸以肽键形成的甘草次酸衍生物、甘草次酸的3位取代的糖是五碳糖基、甘草次酸的3位取代糖是六碳糖基、甘草次酸3位取代是至少一个五碳糖和至少一个六碳糖连接糖基、甘草次酸的3位取代糖基是取代的五碳糖和取代的六碳糖连接形成的糖基。
通过发明人对构效关系研究发现,在通式I的母核结构对于活性是必须的,因此任何取代的通式I结构的化合物都是发明人的创造性劳动成果,也在本发明的保护范围内。
在一种具体的实施方式中,本发明化合物是甘草酸,甘草酸是甘草提取物,现在也可以通过人工合成获得。
在一种具体的实施方式中,本发明化合物是甘草次酸(Glycyrrhetinic acid,GA),其是天然产物甘草酸(Glycyrrhizin,GL)的三萜苷元。
在一种具体的实施方式中,本发明化合物是甘草次酸的两个差向异构体18α-甘草次酸 (18α-GA)和18β-甘草次酸(18β-GA)。
在一种具体的实施方式中,本发明化合物是甘珀酸(Carbenoxolone,CBX),其是人工合成的18β-GA衍生物。
在一种具体的实施方式中,本发明的化合物是甘草次酸酯,包括不限于甘草次酸甲酯、甘草次酸乙酯、甘草次酸丙酯、甘草次酸异丙酯、以及任何脂肪酸与甘草次酸形成的酯;
在一种具体实施方式中,本发明的化合物是甘草次酸谷氨酰胺,任何伯胺与甘草次酸形成的酰胺类化合物;
在一种具体实施方式中,本发明的化合物是半乳糖取代的甘草次酸等化合物。
本发明系列化合物通过对TMEM16A/CaCCs的作用最终用于治疗相关疾病的机理图如图1所示。
定义:
本发明涉及化合物的母核结构为甘草酸类似物,为了在描述上的方便,以甘草次酸的结构为例,对结构中的C和六元环进行编号如下:
“糖基”是通式I的化合物中R3的部分,其通过糖苷键与通式I除R1以外的其他部分连接形成本发明化合物。
“烷基”指含有1-10个碳原子(在另一个实例中,1-6个碳原子)的直链或支链的饱和烃基。说明性的实例包括不限于甲基、乙基、异丙基、伯丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、己基、3-甲基己基、2,2-二甲基戊基、2,3-二甲基己基、庚基、辛基、壬基和癸基。
“芳基”指单个六元至十四元、单或双碳环,其中单环为芳族的且双环中的至少一个环是芳族的。代表性的实例包括苯基、萘基等。
“芳基烷基’指被1个或2个如本文定义的芳基基团取代的如本文定义的烷基。
“芳基羰基”C(O)R基团,其中R为如本文定义的芳基。
“烯氧基”指R基团,其中R为如本文定义的芳基。
“羧基”指C(O)OH基团。
“环烷基”指至少l个碳环原子的单环或稠合的二环、饱和的或部分不饱和的(但不是芳族的)烃基。稠合的二环烃基包括桥环。环烷基包括螺环烷基环。除非另有说明,否则基团的化合价可以位于该基团内的任何环的任何原子,只要价数规则允许。
“药学上可接受的盐”指本发明化合物与酸或碱所形成的适合用作药物的盐,药学上可接受的盐包括无机盐和有机盐包括不限于苯磺酸盐、琥珀酸盐、钠盐等。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅说明本发明而用于限制本发明期望保护的范围。下列实施例中未注明具体条件的实验方式,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则份数和百分比为重量份和重量百分比。常规的原料是常用购买获得。
本发明化合物1-1(18β-GA):购自阿达玛斯试剂有限公司
本发明化合物1-2(18α-GA):购自GLPBIO公司
本发明化合物1-3(甘珀酸,Carbenoxolone,CBX):购自Sigma-Aldrich公司.
本发明化合物甘草酸(GL):购自Sigma-Aldrich公司。
实施例1:采用全细胞膜片钳技术,测试本发明化合物1-1,1-2,1-3化合物对TMEM16A/CaCCs的增大作用的量效关系研究(图1)。
1.TMEM16A稳定转染CHO细胞的培养及铺片
将稳定转染TMEM16A的CHO细胞在含有1%非必需氨基酸,600μg/ml G418,10%胎牛血清(Gibco,美国)和抗生素(100IU/ml青霉素G和100μg/ml链霉素;Solarbio,中国)的F-12K(Solarbio,China)中培养。细胞在37℃、含5%CO2空气的饱和湿度细胞培养箱中培养。0.25%胰酶消化。细胞接种在24孔板的玻璃盖玻片上。细胞接种12小时后进行膜片钳记录,48小时内使用细胞。
2.电生理膜片钳记录TMEM16A/CaCCs电流
电流记录采用Axon patch 200B或700B膜片钳放大器,信号采集应用pClamp 10.0软件(Axon Instruments,CA),滤波为2kHz。膜片钳电极由水平电极拉制仪(P-97,Sutterinstrument,USA)经多步程序拉制而成,并使用抛光仪进行抛光,充灌电极内液后测定其电阻为3.0~4.0MΩ。电流记录在室温(23~25℃)下进行,灌流槽中液体流速为1~2 ml/min。细胞外液(mM):160NaCl,2.5KCl,2CaCl2,1MgCl2,10HEPES,8glucose, pH 7.4。电极内液(mM):130CsCl,10EGTA,6CaCl2,1MgCl2,10HEPES,,2ATP, pH 7.3(free Ca2+concentration:~135nM)。在实验中使用四道或八通道灌注笔(250μm尖端,AutoMateScientific,Inc.,CA,USA)用于单细胞给药。
3.药物溶液配制
实验中所用药物均溶于DMSO中,配成100mM母液。实验时用细胞外液稀释至合适浓度。
4.实验结果
在TMEM16A稳定转染的CHO细胞系上,利用全细胞膜片钳技术,在[Ca2+]i=135nM条件下,检测甘草次酸类化合物对TMEM16A/CaCCs的调节作用。记录所用电压刺激程序见图2a。18β-GA(本发明化合物1-1,图2b,30μM)、18α-GA(本发明化合物1-2,图 2b,30μM)及Carbenoxolone/CBX(本发明化合物1-3,图2b,30μM)对TMEM16A/CaCCs 的作用典型图。18α-GA和18β-GA对TMEM16A/CaCCs电流的内向和外向电流均具有强大的增大作用。CBX具有较弱的激活作用。甘草酸(glycyrrhizin,GL)无作用。统计学结果见图2c。
实施例2:本发明化合物1-1对外源性表达的TMEM16A/CaCCs的增大作用的药理学鉴定(图3)。
如图2所示,18β-GA(30μM,本发明化合物1-1)可显著增大CHO细胞上外源性表达的TMEM16A/CaCCs电流。此电流可被TMEM16A/CaCCs阻断剂MONNA(10μM,图3a)、cepharanthine(30μM,图3b)所阻断。记录所用电压刺激程序见图3c。统计学结果见图3d。上述实验结果证明了18β-GA增大的电流为TMEM16A/CaCCs电流。18β-GA、MONNA及cepharanthine作用的电流图取自相应图3a和3b中标注位置。
实施例3:本发明化合物1-1,1-2,1-3化合物对TMEM16A/CaCCs的增大作用的量效关系研究(图4)。
18β-GA(本发明化合物1-1)、18α-GA(本发明化合物1-2)及CBX(本发明化合物 1-3)增大CHO细胞稳定表达的TMEM16A/CaCCs电流的量效关系。记录所用电压刺激程序见图3d。药物作用采用给药后电流幅度(Idrug)/对照电流幅度(Icontrol)表示。量效关系曲线采用Logistic方程拟合。18β-GA、18α-GA的半最大效应浓度(EC50)及最大效应(Emax) 如图4b所示。
实施例4:本发明化合物1-1,1-2,1-3化合物对TMEM16A/CaCCs的通道动力学的影响研究(图5)。
采用连续的电压刺激程序(记录所用电压刺激程序见图5a),可以观察到18β-GA(本发明化合物1-1)、18α-GA(本发明化合物1-2)、CBX(本发明化合物1-3)以及GL对TMEM16A/CaCCs激活及去激活时程的调节作用。结果如图5b所示,在135nM内钙浓度,我们记录到了一个较小的TMEM16A/CaCCs电流。18β-GA、18α-GA(30μM、100μM) 可浓度依赖性增大TMEM16A/CaCCs。并且,在30μM浓度下和100μM浓度下,18α-GA、 18β-GA使通道激活加快,而去活时程减慢。而CBX在30μM、100μM浓度时,作用微弱, GL没有作用。统计学结果见图5c。
实施例5:本发明化合物1-1与目前已知化合物的对比数据结果(图6)。
采用图6a所示电压刺激程序,可以观察到30μM 18β-GA(本发明化合物1-1)可显著增大TMEM16A/CaCCs。而已报道的TMEM16A/CaCCs激动剂Eact,在30μM浓度时却未显示增大TMEM16A/CaCCs的作用(图6b)。另一已报道的TMEM16A/CaCCs激动剂 NS1619,在30μM浓度时也仅显示微弱的TMEM16A/CaCCs增大作用(图6c)。统计学结果见图6d。
实施例6:本发明化合物1-1激活TMEM16A/CaCCs不依赖于其引发的内钙升高
采用内质网钙库排空剂(Ca2+ATP酶泵抑制剂)thapsigargin(TG,2μM)作为阳性对照药(图7a-7c)证明本发明化合物1-1对TMEM16A/CaCCs的激活作用不依赖于它引发的[Ca2 +]i升高,具体结果如下:①Thapsigargin虽然引发[Ca2+]i升高,但并不激活 TMEM16A/CaCCs。本发明化合物1-2显示出对TMEM16A/CaCCs强大、稳定的激活效应 (图7d);②排空内质网的钙库不影响甘草次酸的激活作用(图7d);③甘草酸(GL) 同样引起一过性的[Ca2+]i升高,却对TMEM16A/CaCCs没有激活作用(图7e)。以上数据表明,本发明化合物1-1对TMEM16A/CaCCs的激活作用不依赖于其引发的[Ca2+]i升高,而是直接作用在通道上,而非增加内钙浓度而激活。
实施例7:本发明化合物1-1激活TMEM16A/CaCCs的内钙依赖性.
在不同[Ca2+]i条件下检测本发明化合物1-1(18β-GA)对TMEM16A/CaCCs的激活作用,结果如下:①在0[Ca2+]i条件下,18β-GA(30μM)失去了活性(图8a-8b);②随着[Ca2+]i的升高,18β-GA(30μM)显示出相似的激活效应;采用穿孔膜片钳不干扰[Ca2+]i条件下,18β-GA具有相似的激活效应(图8c-8d)。
实施例8本发明化合物1-1对分泌细胞内源性TMEM16A/CaCCs的增大作用
TMEM16A在分泌上皮细胞和腺体中特异性高表达,在调节内、外分泌腺和上皮细胞的液体分泌中起重要作用。因此,我们在多个上皮细胞和腺细胞中检测18β-GA对内源性TMEM16A/CaCC的影响。如图9所示,本发明化合物1-2(30μM)强烈激活LA795和 A549肺腺癌、MCF-7乳腺癌、PC-3人前列腺癌、CFPAC-1胰腺癌、HCT116人结直肠癌、 A253和HSG人唾液腺癌细胞(图9a、9c);对于HBE人支气管上皮细胞、HCE人结肠上皮细胞以及HCjE人结膜上皮细胞具有相对较弱的激活作用(图9b、9c)。
实施例9:本发明化合物2的合成
将7.88g商购甘草酸加入到三口瓶中,用150ml甲醇溶解,回流反应6小时,通过薄层检测发现除原料外,有一个新的产物出现停止反应,将甲醇低压旋转蒸干,获得产品,通过硅胶柱进行分离,获得2.50g本发明化合物2,收率31.1%,通过NMR H1检测发现相比原料在化学位移3.6左右多3个氢,质谱M+1峰m/z是802,确认为本发明化合物2。
实施例10:本发明化合物3的合成
将4.56g的18α甘草次酸溶解于100ml甲醇钠的甲醇溶液中,室温反应2小时,通过薄层检测发现除原料外,有一个新的产物出现,原料已经消失,停止反应,将甲醇低压旋转蒸干,获得产品,通过硅胶柱进行分离,获得4.25g本发明化合物3,收率90.4%,通过NMR H1检测发现相比原料在化学位移3.6左右多3个氢,质谱M+1峰是471,确认为本发明化合物3,如下式所示。
实施例11:本发明化合物4的合成
将4.56g的18β甘草次酸溶解于100ml甲醇钠的甲醇中,室温反应4小时,通过薄层检测发现除原料外,有一个新的产物出现,原料已经消失,停止反应,将甲醇低压旋转蒸干,获得产品,通过硅胶柱进行分离,获得3.68g本发明化合物4,收率78.2%,通过 NMR H1检测发现相比原料在化学位移3.6左右多3个氢,质谱M+1峰是471,确认为本发明化合物4,如下式所示。
实施例12:本发明化合物5的合成
将4.56g的18β甘草次酸溶解于100ml乙醇钠的乙醇溶液中,室温反应4小时,通过薄层检测发现除原料外,有一个新的产物出现,原料已经消失,停止反应,将溶剂低压旋转蒸干,获得产品,通过硅胶柱进行分离,获得4.36g产物,收率90%,通过NMR H1 检测发现相比原料在化学位移4.21有一个2个氢的dd峰,在1.2处有一个3个氢的三重峰,质谱M+1峰是484,确认为本发明化合物5,如下式所示。
实施例13:本发明化合物6的合成
将4.56g的18β甘草次酸溶解于100ml异丙醇钠的异丙醇溶液中,室温反应6.5小时,通过薄层检测发现除原料外,有一个新的产物出现,原料已经消失,停止反应,将溶剂低压旋转蒸干,获得产品,通过硅胶柱进行分离,获得3.6g产物,收率72.3%,通过NMR H1 检测发现相比原料在化学位移4.0有一个1个氢的多重峰,在1.2处有2个6个氢的三重峰,质谱M+1峰是498,确认为本发明化合物6,如下式所示。
实施例14:本发明化合物7的合成
将4.56g的18α甘草次酸加入5g的乙酸酐和1g无水醋酸钠,搅拌升温至回流,保温5小时,在搅拌条件下加入15%质量分数的碳酸钠,通过薄层检测发现除原料外,有一个新的产物出现,原料已经消失,停止反应。然后用15%的氯化钠溶液萃取洗涤至中性,分出有机相,之后经过干燥,通过硅胶柱进行分离,获得3.2g产物,收率64.2%,通过 NMR H1检测发现相比原料在化学位移2.0有3个氢的s峰,质谱M+1峰是498,确认为本发明化合物7,如下式所示。
实施例15:测定本发明化合物2-7对TMEM16A/CaCCs的作用影响
按照实施例1中方法,对化合物2-7进行测定发现,在TMEM16A稳定转染的CHO 细胞系上,利用全细胞膜片钳技术,在[Ca2+]i=100nM条件下,检测化合物对 TMEM16A/CaCCs的调节作用,结果是上述化合物增大TMEM16A/CaCCs的作用是可逆的,且均不影响TMEM16A/CaCCs的翻转电位。
Claims (10)
1.一种结构如通式I所示,其特征在于,其作为TMEM16A激动剂,如通式I所示,其可变异构体或其互变异构体,其药学上可接受的盐、前药和酯,
其中,R1独立地选自-S-R3或-O-R3;
R2独立地选自-NR5R6或-O-R7;
R3独立地选自氢、氕、氘、氚、-(C=O)R4,单糖糖基、二糖糖基、多糖糖基、R4取代的单糖糖基、R4取代的二糖糖基、R4取代的多糖糖基;
R4独立地选自烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代;
所述单糖糖基的糖是葡萄糖,甘露糖、半乳糖、果糖、阿拉伯糖,木糖,D-核糖、脱氧核糖、鼠李糖、半乳糖醛酸、葡萄糖醛酸、山梨糖醇;
所述二糖糖基的糖是麦芽糖、异麦芽糖、乳糖、纤维二糖、蔗糖、龙胆二糖、海藻二糖、蜜二糖、软骨素二糖、透明质二糖、菊粉二糖;
所述多糖是至少2个单糖连接而成;
R5、R6、R7独立地选自氢、氕、氘、氚、烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代;
-NR5R6是氨基酸的氨基端的一个H被取代后形成基团,所述氨基酸选自甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、甲硫氨酸、脯氨酸、色氨酸、丝氨酸、酪氨酸、半胱氨酸、苯丙氨酸、天冬酰胺、谷氨酰胺、苏氨酸、天冬氨酸、谷氨酸、赖氨酸、精氨酸或组氨酸。
2.如权利要求1所述化合物、其可变异构体或其互变异构体,其药学上可接受的盐、前药和酯,其中所述
R1是-O-R3;
R2是-O-R7;
R3独立地选自氢、氕、氘、氚、-(C=O)R4,单糖糖基、二糖糖基、多糖糖基、R4取代的单糖糖基、R4取代的二糖糖基、R4取代的多糖糖基;
R4独立地选自烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代;
所述单糖糖基的糖是葡萄糖,甘露糖、半乳糖、果糖、阿拉伯糖,木糖,D-核糖、脱氧核糖、鼠李糖、半乳糖醛酸、葡萄糖醛酸、山梨糖醇;
所述二糖糖基的糖是麦芽糖、异麦芽糖、乳糖、纤维二糖、蔗糖、龙胆二糖、海藻二糖、蜜二糖、软骨素二糖、透明质二糖、菊粉二糖;
所述多糖是至少2个单糖连接而成;
R7独立地选自氢、氕、氘、氚、烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代。
3.如权利要求1或2所述化合物、其可变异构体或其互变异构体,其药学上可接受的盐、前药和酯,其中所述R1是-O-R3;R2是-O-R7,R3独立地选自H、氘、-(C=O)R4,单糖糖基、二糖糖基、多糖糖基;
R4独立地选自烷基、芳基、芳基烷基、环烷基、环烷基烷基、杂环烷基、杂环烷基烷基、杂芳基、杂芳基烷基;其中每个烷基、环烷基、芳基、杂芳基、杂环烷基烷基或杂环烷基,无论单独还是作为另一个基团的一部分,任选地可以被0、1或多个独立地选自氢、羟基、卤素、卤代烷基、烷氧基、烷基、烷基羰基、烷氧基羰基、羧基烷基,羧基芳基、氨基、酰胺基、氨酰基的基团取代。
8.一种药物组合物,包含权利要求1-5所述化合物、其可变异构体或其互变异构体、其药学上可接受的盐、前药或酯,以及可药用赋形剂或载体。
9.如权利要求1-5述化合物、其可变异构体或其互变异构体、其药学上可接受的盐、前药或酯和权利要求8所述药物组合物在制备通过激动TMEM16A治疗疾病的药物中应用。
10.如权利要求9所述应用,其中所述疾病为囊性纤维化、唾液腺功能障、干眼症、口腔干燥症、胆汁淤积性肝病、糖尿病、肠动力减退症、慢性阻塞性肺炎、哮喘、肺部感染。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021103219928 | 2021-03-25 | ||
CN202110321992 | 2021-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115677813A true CN115677813A (zh) | 2023-02-03 |
Family
ID=85060228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210302603.1A Pending CN115677813A (zh) | 2021-03-25 | 2022-03-25 | 化合物在tmem16a激动剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115677813A (zh) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040147494A1 (en) * | 2001-03-08 | 2004-07-29 | Potter Barry Victor Lloyd | Use |
CN1911954A (zh) * | 2006-09-14 | 2007-02-14 | 杭州耀恒医药科技有限公司 | 带氨基酸的甘草酸衍生物、其制备方法及含有它们的药物组合物 |
CN101062937A (zh) * | 2006-04-29 | 2007-10-31 | 江苏正大天晴药业股份有限公司 | 18α-甘草酸衍生物及其制剂 |
CN102399256A (zh) * | 2011-11-24 | 2012-04-04 | 江苏省原子医学研究所 | 甘草次酸衍生物、其制备方法、其药物组合物和其在制备抗肿瘤药物中的应用 |
US20140073700A1 (en) * | 2012-09-10 | 2014-03-13 | Abbvie Inc. | Glycyrrhetinic acid derivatives and methods of use thereof |
CN104250278A (zh) * | 2013-06-28 | 2014-12-31 | 江苏天晟药业有限公司 | 一种18α-甘草酸次酸的制备方法 |
CN104876997A (zh) * | 2015-03-01 | 2015-09-02 | 李玉山 | 一种甘草次酸3-位羟基结构修饰方法 |
CN104926912A (zh) * | 2015-02-16 | 2015-09-23 | 内蒙古医科大学 | 甘草次酸衍生物的合成及其用途 |
WO2017083795A1 (en) * | 2015-11-13 | 2017-05-18 | Pietro Paolo Sanna | Methods and compositions for treating alcohol use disorders |
CN107118249A (zh) * | 2017-05-16 | 2017-09-01 | 沈阳药科大学 | 18β‑甘草次酸衍生物及其应用 |
CN107693555A (zh) * | 2017-11-08 | 2018-02-16 | 莫玉艳 | 一种治疗糖尿病的药物及用途 |
CN108251489A (zh) * | 2018-01-16 | 2018-07-06 | 浙江大学 | 一种利用甘草生物转化生成甘草次酸的方法 |
CN108815154A (zh) * | 2018-08-01 | 2018-11-16 | 广东药科大学 | 橙皮素、桔皮素与甘草次酸在抑制氯离子通道中的应用 |
CN110818765A (zh) * | 2018-08-07 | 2020-02-21 | 重庆圣华曦药业股份有限公司 | 一种顺式甘草酸异构化的方法 |
CN111018938A (zh) * | 2019-12-10 | 2020-04-17 | 中国人民解放军第二军医大学 | 一种五环三萜类甘草次酸衍生物及制备方法与应用 |
CN111233965A (zh) * | 2020-03-31 | 2020-06-05 | 江苏崇佩生物科技有限公司 | 一种甘草次酸衍生物lgt及其制备方法和应用 |
CN111686152A (zh) * | 2020-07-13 | 2020-09-22 | 北京安德普泰医疗科技有限公司 | 一种治疗淋巴水肿的外用组合物、凝胶剂及其制备方法 |
-
2022
- 2022-03-25 CN CN202210302603.1A patent/CN115677813A/zh active Pending
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040147494A1 (en) * | 2001-03-08 | 2004-07-29 | Potter Barry Victor Lloyd | Use |
CN101062937A (zh) * | 2006-04-29 | 2007-10-31 | 江苏正大天晴药业股份有限公司 | 18α-甘草酸衍生物及其制剂 |
CN1911954A (zh) * | 2006-09-14 | 2007-02-14 | 杭州耀恒医药科技有限公司 | 带氨基酸的甘草酸衍生物、其制备方法及含有它们的药物组合物 |
CN102399256A (zh) * | 2011-11-24 | 2012-04-04 | 江苏省原子医学研究所 | 甘草次酸衍生物、其制备方法、其药物组合物和其在制备抗肿瘤药物中的应用 |
US20140073700A1 (en) * | 2012-09-10 | 2014-03-13 | Abbvie Inc. | Glycyrrhetinic acid derivatives and methods of use thereof |
CN104250278A (zh) * | 2013-06-28 | 2014-12-31 | 江苏天晟药业有限公司 | 一种18α-甘草酸次酸的制备方法 |
CN104926912A (zh) * | 2015-02-16 | 2015-09-23 | 内蒙古医科大学 | 甘草次酸衍生物的合成及其用途 |
CN104876997A (zh) * | 2015-03-01 | 2015-09-02 | 李玉山 | 一种甘草次酸3-位羟基结构修饰方法 |
WO2017083795A1 (en) * | 2015-11-13 | 2017-05-18 | Pietro Paolo Sanna | Methods and compositions for treating alcohol use disorders |
CN107118249A (zh) * | 2017-05-16 | 2017-09-01 | 沈阳药科大学 | 18β‑甘草次酸衍生物及其应用 |
CN107693555A (zh) * | 2017-11-08 | 2018-02-16 | 莫玉艳 | 一种治疗糖尿病的药物及用途 |
CN108251489A (zh) * | 2018-01-16 | 2018-07-06 | 浙江大学 | 一种利用甘草生物转化生成甘草次酸的方法 |
CN108815154A (zh) * | 2018-08-01 | 2018-11-16 | 广东药科大学 | 橙皮素、桔皮素与甘草次酸在抑制氯离子通道中的应用 |
CN110818765A (zh) * | 2018-08-07 | 2020-02-21 | 重庆圣华曦药业股份有限公司 | 一种顺式甘草酸异构化的方法 |
CN111018938A (zh) * | 2019-12-10 | 2020-04-17 | 中国人民解放军第二军医大学 | 一种五环三萜类甘草次酸衍生物及制备方法与应用 |
CN111233965A (zh) * | 2020-03-31 | 2020-06-05 | 江苏崇佩生物科技有限公司 | 一种甘草次酸衍生物lgt及其制备方法和应用 |
CN111686152A (zh) * | 2020-07-13 | 2020-09-22 | 北京安德普泰医疗科技有限公司 | 一种治疗淋巴水肿的外用组合物、凝胶剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
R. M. KONDRATENKO: "Synthesis and Antiulcer Activity of 3-O-Acylated Glycyrrhetic Acid Methylates", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 5, pages 242 - 246 * |
TAKANORI SAEKI: "Conversion of Ca 2þ oscillation into propagative electrical signals by Ca 2þ -activated ion channels and connexin as a reconstituted Ca 2þ clock model for the pacemaker activity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, no. 510, pages 242 - 247 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9884863B2 (en) | STAT3 inhibitor | |
ES2895490T3 (es) | Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa | |
JP6982004B2 (ja) | ソベチロム誘導体 | |
US11858888B2 (en) | Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases | |
US20080027023A1 (en) | Antiproliferative Compositions Comprising Aryl Substituted Xylopyranoside Derivatives | |
CN101679341B (zh) | 作为粘液分泌刺激剂的3',4',5-三甲氧基黄酮衍生物、其制备方法以及包含该化合物的药物组合物 | |
US9522935B2 (en) | Commands and method of treating cancer via RHO pathway | |
US20140024113A1 (en) | Compounds for treating cancer and other diseases | |
Li et al. | Novel harmine derivatives for tumor targeted therapy | |
JP5425799B2 (ja) | 抗腫瘍活性を有する水溶性トリテルペンフェノール化合物及びその調製方法 | |
Cummins et al. | Antifibrosis effect of novel oridonin analog CYD0618 via suppression of the NF-κB pathway | |
JP2004513176A (ja) | サイトゾルのホスホリパーゼのモジュレーターとしてのグリセロホスホイノシトール誘導体 | |
CN115677813A (zh) | 化合物在tmem16a激动剂中的应用 | |
WO2016184400A1 (zh) | 一种新的18α-甘草次酸衍生物及其医药用途 | |
US20060183794A1 (en) | Drug composition containing nf-kb inhibitor | |
JP2021523934A (ja) | ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物 | |
He et al. | Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC) | |
RU2629929C2 (ru) | 2β,3α,5α-ТРИГИДРОКСИ-АНДРОСТ-6-ОН, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
AU2014253584B2 (en) | Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof | |
Dai et al. | Anti-tumor effects of novel alkannin derivatives with potent selectivity on comprehensive analysis | |
Liu et al. | Sparganii Rhizoma alleviates pulmonary fibrosis by inhibiting fibroblasts differentiation and epithelial-mesenchymal transition mediated by TGF-β1/Smad2/3 pathway | |
TW202128678A (zh) | 包含噻吩中心環的固醇調節區域結合蛋白質(srebp)抑制劑 | |
US20140179624A1 (en) | Cytoprotective derivatives of avicin d and methods of making and using thereof | |
US9580399B2 (en) | Geranyl flavonoid derivative with improved water solubility, a method for preparing the same, and a method for treating cancer using the same | |
US9175030B2 (en) | Derivatives of avicin D and methods of making and using thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 050090 No. 326, Xinshi South Road, Qiaoxi District, Shijiazhuang City, Hebei Province Applicant after: Hebei University of Traditional Chinese Medicine Address before: 050090 No. 326, Xinshi South Road, Qiaoxi District, Shijiazhuang City, Hebei Province Applicant before: HEBEI University OF CHINESE MEDICINE |
|
CB02 | Change of applicant information |